Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference

CEO and President Joe Payne outlined the company’s current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner ...
Motley Fool Australia

Forget CSL shares, I'd buy this booming biotech stock instead

CSL shares have decreased 36.54% year-to-date, impacted by a sell-off after FY25 results and guidance downgrades, though analysts see a potential 53.52% upside. Positioned for expansion with stem cell ...
Motley Fool Australia

Where will CSL shares be in 5 years?

CSL shares have seen a significant downturn due to recent challenges, yet analysts see potential for recovery, with a projected rebound to $275, driven by its strong foundation and global healthcare ...
Hosted on MSN

Why did Macquarie just downgrade CSL shares?

CSL Ltd (ASX: CSL) shares are having a poor start to the week. In afternoon trade, the biotechnology giant's shares are down 1.5% to $180.99. There are a couple of reasons why investors have been ...